Judo Bio Named to Endpoints 11 List of Biotech’s Most Promising Startups
CAMBRIDGE, Mass., September 19, 2025 – Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivery to the kidney, today announced that it has been named as one of the Endpoints 11 most promising private biotechnology companies of 2025. Judo Bio was selected by the Endpoints News editorial team because of the company’s strengths in science, leadership, investors and strategy to shape future innovation to create breakthrough therapies for patients.
“On behalf of the entire Judo Bio team, we are honored to be recognized as an Endpoints 11 company,” said Rajiv Patni, Chief Executive Officer of Judo Bio. “This award serves as a testament to the caliber of our team and unique platform and emerging pipeline. We are excited to continue our momentum towards bringing kidney-targeted RNA medicines into the clinic.
The 2025 Endpoints 11 winners were announced at an awards gala held in Boston on Thursday, September 18.
Judo Bio has discovered a novel approach to create oligonucleotide medicines targeted to the kidney, an organ that has been challenging to access for genetic medicines. The company has completed preclinical studies successfully demonstrating receptor-mediated delivery of oligonucleotides to the kidney with proprietary ligand-siRNA conjugates that silence multiple target genes. Based on Judo Bio’s ongoing work showing the ability of its ligand-siRNA conjugates to achieve therapeutic gene silencing in the kidney, the company is advancing its first drug programs to the clinic.
About Judo Bio
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With its STRIKE (Selectively Targeting RNA Into KidnEy) platform, the company is using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated uptake by specific kidney cell types, resulting in gene silencing of disease-modifying target genes. Judo Bio’s initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases. Located in Cambridge, MA, Judo Bio’s team and advisors include experts in oligonucleotide therapies and innovative drug development. For more information, visit www.judo.bio and follow us on LinkedIn.
Media contact:
Kathryn Morris
The Yates Network LLC
914-204-6412
